News

Hosted on MSN2mon
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has ... the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria. C3G is a progressive and ultra-rare kidney disease that is ...
Benzinga.com10mon
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
On Thursday, the FDA granted accelerated approval to Novartis AG’s NVS Fabhalta ... at risk of rapid disease progression. In December 2023, the FDA approved Fabhalta as the first oral ...
Yahoo Finance2mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
On Thursday, the U.S. Food and Drug Administration ... within the Novartis kidney disease portfolio since August 2024, when Fabhalta was granted accelerated approval by the FDA for the reduction ...
Yahoo Finance2mon
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce ...
Reuters10mon
US FDA approves Novartis' kidney disease drug
Aug 7 (Reuters) - The U.S. Food and Drug Administration has approved the use of Novartis' (NOVN.S), opens new tab drug to reduce excess protein in the urine of patients with a type of kidney ...
Benzinga.com2mon
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
This is the third US approval for Fabhalta and its second within the Novartis kidney disease portfolio since August 2024, when Fabhalta was granted accelerated approval by the FDA for the ...